LONRF2P5

Across TCGA pan-cancer cohorts, LONRF2P5 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated LONRF2P5 data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher LONRF2P5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LONRF2P5 expression acts as an unfavorable survival marker.

THCA, OV, and STAD are the cancer types where LONRF2P5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Tertile	All	0.717	0.945	<.001	36	view →
OV	DFS	Tertile	III,IV	0.305	0.389	.020	18	view →
STAD	OS	Tertile	II,III,IV	0.540	0.683	.029	9	view →
BRCA	OS	Tertile	II,III,IV	0.812	0.914	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LONRF2P5–THCA (DFS)

Open the THCA breakdown →